I'll research KVUE (Kenvue) before writing the preview. Let me gather recent filings, earnings history, and news in parallel.Let me read the most recent earnings documents and search for recent news on KVUE.This is a special situation — Kenvue is being acquired by Kimberly-Clark. Let me gather the deal terms, prior-year Q2 comps, and current stock price to frame the merger-arb angle.Let me verify the exact merger terms and recent regulatory/litigation developments via web search.Let me check the latest deal-status and Tylenol litigation developments closest to the report date.I have what I need. Here's the earnings preview.
Kenvue is no longer a standalone equity story. On November 2, 2025 it agreed to be acquired by Kimberly-Clark (KMB), and shareholders of both companies overwhelmingly approved the deal on January 29, 2026. As a result, the stock now trades as a spread to the Kimberly-Clark deal terms, not off its quarterly operating results. Management has stated it will not host a call or provide forward guidance while the transaction is pending, so tomorrow's release will be a data dump — the numbers matter mostly as a check on deal risk (a MAC/business-deterioration trigger) rather than as a driver of the multiple.
Each KVUE share converts into $3.50 in cash + 0.14625 KMB shares. Each Kenvue share would be converted into 0.14625 shares of K-C common stock plus $3.50 in cash, which equated to about $21.01 per share at K-C's October 31, 2025 closing price and $18.53 at December 15, 2025 — the equity value swing shows how much the payout floats with KMB stock. This valuation places the equity portion of the deal at approximately $40 billion.
Using recent closes (KMB ≈ $112.40, KVUE ≈ $19.66 on 8/5/26):
| Item | Value |
|---|---|
| Cash component | $3.50 |
| Stock component (0.14625 × $112.40) | ~$16.44 |
| Implied deal value / share | ~$19.94 |
| KVUE last price | ~$19.66 |
| Gross spread | ~$0.28 (~1.4%) |
A ~1.4% gross spread with an expected H2 2026 close implies a mid-to-high-single-digit annualized return — the market is pricing high confidence the deal closes, but not certainty. Because ~82% of the consideration is KMB stock, KVUE holders effectively have exposure to Kimberly-Clark; note KMB fell sharply on announcement (from ~$120 to ~$100) as KVUE jumped (~$14.4 → ~$16.1), and KMB has since recovered toward ~$112, pulling the implied value back up.
The clearance path is well advanced but not finished: - The waiting period applicable to the Kenvue Acquisition under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expired on February 4, 2026. (U.S. antitrust cleared.) - Kimberly-Clark's intended acquisition of Kenvue has been cleared by the European Commission under the terms of the Foreign Subsidies Regulation, but per the same report the deal still needs merger approval from the EU regulator. - Management continues to guide to a second-half-2026 close, subject to remaining foreign regulatory approvals and customary conditions.
Watch for: any update in the release language on the closing timeline or foreign approvals. The base case is that the deal closes and KVUE may not report many more quarters as a public company. The main risk to the arb is a change in the EU merger review or a KMB stock drawdown (which lowers the payout).
The relevant question for deal risk is whether the operating recovery that began late in 2025 is holding. The trajectory has inflected positive:
| Metric | Q2'25 (comp) | Q1'26 (latest) |
|---|---|---|
| Net sales | $3,839M (−4.0%) | $3,909M (+4.5%) |
| Organic sales | −4.2% | +0.7% |
| Adj. gross margin | 60.9% | 60.8% |
| Adj. operating margin | 22.7% | 24.0% |
| Adj. diluted EPS | $0.29 | $0.32 |
Q1'26 marked the second consecutive quarter of net and organic sales growth, with meaningful year-over-year margin and EPS expansion driven by supply-chain productivity and cost actions (Our Vue Forward + the 2026 Restructuring Initiative). Segment color to carry into Q2: - Self Care (Tylenol, Nicorette, Zyrtec): the soft spot — organic −2.3% in Q1 on weak cold/flu seasons, though U.S. consumption and Tylenol share/recommendations were improving sequentially. - Skin Health & Beauty (Neutrogena, Aveeno, OGX): the bright spot — +5.0% organic in Q1 on innovation and eCommerce. - Essential Health (Listerine, Band-Aid, Johnson's, baby care): +1.5% organic, steady.
Because Q2'25 was a weak quarter (organic −4.2%), the year-over-year comparison is easy — a return to modest growth would confirm the turn. A surprise re-acceleration of declines would be the only "fundamental" read that could reopen deal-risk debate.
This is the key idiosyncratic wildcard that has whipsawed the stock and remains unresolved. After the federal MDL was dismissed on Daubert grounds (plaintiffs' causation experts deemed inadmissible), a federal appeals court revived lawsuits that claim Kenvue hid alleged risks that Tylenol could cause autism in children whose mothers took the medication while pregnant — the appeals court concluded that the experts used accepted scientific methods and offered permissible interpretations of the research on prenatal acetaminophen exposure and neurodevelopmental disorders. The Q1 release already flagged that Tylenol brand trust had stabilized "at the same levels as in early September" (following the fall-2025 acetaminophen–autism political flare-up). Litigation risk sits with KVUE/KMB regardless of deal close; watch for any updated disclosure or reserve language.
Note: figures above are drawn from Kenvue's Q1 2026 and Q2 2025 earnings releases and public deal disclosures. Because there is no call or guidance, the release itself (segment organic growth, margins, and any deal-timeline language) will be the only new information.